China Pharma Files Prospectus Supplement With The U.S. SEC Under Which The Company May Offer And Sell From Time To Time Shares Of Common Stock, With An Aggregate Offering Price Of Up To $600,000
Author: Benzinga Newsdesk | December 13, 2024 08:01am
China Pharma Holdings, Inc. (NYSE:CPHI) ("China Pharma," or the "Company"), a specialty pharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (the "SEC") under which the Company may offer and sell from time to time shares of common stock, par value $0.001 per share (the "Common Stock"), with an aggregate offering price of up to $600,000 (the "Financing").
Posted In: CPHI